血清TPS、CEA、Pro-GRP和CYFRA21—1水平在肺癌患者中的临床意义

Clinical Value of Serum TPS, CEA, Pro-GRP and CYFRA21-1 in Patients with Lung Cancer

背景与目的血清肿瘤标志物在肺癌的诊断、疗效、预后判断中起着重要作用。本研究探讨血清组织多肽特异性抗原（TPS）在肺癌患者中的临床意义。并与癌胚抗原（CEA）、胃泌素释放肽前体（Pro—GRP）、细胞角蛋白19片段（CYFRA21—1）作比较。方法应用ELISA检测82例肺癌患者化疗前及部分患者化疗后4种标志物水平。结果肺癌患者TPs、CEA、Pro-GRP阳性率及水平显著高于肺部良性疾病组和健康对照组。广泛期SCLC患者TPS阳性率显著高于局限期患者。患者化疗后TPS、CEA、Pro—GRP阳性率及水平均显著下降。非小细胞肺癌患者TPS水平是预后的独立因素。结论TPS在肺癌患者的辅助诊断、疗效观察有较好的临床意义。对非小细胞肺癌的预后判断方面可能有一定价值。

Background and objective Serum tumor markers play important roles in diagnosis, response and prognosis monitoring for lung cancer. The clinical significance of serum level of tissue polypeptide specific antigen （TPS） is investigated in diagnosis, response monitoring and prognosis in patients with lung cancer, Compared with carcinoembryonic antigen （CEA） , precursor of gastrin-releasing peptide （Pro- GRP） , and cytokeratin-19-fragments （CYFRA21-1） . Methods Blood samples of 82 patients with lung cancer before treatment and some after chemotherapy were measured by ELISA for 4 tumor markers. Results Compared with lung benign diseases group and health control group, the positive rates and levels of TPS, CEA, and Pro-GRP in patients with lung cancer were higher with statistically significant difference. TPS in extensive-SCLC was significant higher than that in limited-SCLC. The positive rates and levels of TPS, CEA, and Pro-GRP in patients after treatment had significant decreases compared with before treatment. TPS was an independent prognostic factor for non-small cell lung cancer. Conclusion TPS is valuable to diagnosis, response monitoring for patients with lung cancer, moreover, it maybe a useful factor for prognosis of non-small cell lung cancer.